|
 |
EpogenThis page contains recent news articles, when available, and an overview of Epogen but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.The most commonly used ESAs in the United States are Epogen® (epoetin alfa) Aranesp® (darbebpoetin). The most commonly use ESA in Europe is epoetin-beta ... Cancer Consultants Amgen says court blocks rival Roche anemia drug - Dec 22, 2009 Amgen said a US District Court in Boston ruled that Mircera infringes on five patents supporting Amgen's anemia drugs Aranesp and Epogen. ... The Associated Press Business Briefing - Dec 22, 2009 Amgen sued in 2005 to prevent Roche from challenging the market dominance of its drugs Epogen and Aranesp. Black & Decker Corp., which is being acquired by ... Los Angeles Times The Health Bill Is Scary - Dec 17, 2009 Medicare, for example, has limited cancer patients' access to Epogen, a costly but vital drug that stimulates red blood cell production. ... Wall Street Journal Ready to rumble: Pfizer's generic biotech drug push could pit it against Amgen - Dec 11, 2009 Novartis (NVS), too, has won approval in Europe for biosimilars of Epogen and Pfizer's growth hormone Genotropin. So while Pfizer and other pharmas could ... Daily Finance (blog) Why Obamacare most not be passed. - Dec 18, 2009 Medicare, for example, has limited cancer patients' access to Epogen, a costly but vital drug that stimulates red blood cell production. ... Sussex Sun (blog) Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market ... - Dec 15, 2009 Flexible Market Exclusivity 4.5.3.10 Price Revisions 4.5.3.11 GSK's Retrovir (zidovudine) 4.5.3.12 Amgen's Epogen (erythropoietin) 4.5.3.13 Conclusion 5 ... IT News Online UCSF Physicians Respond to Rep. Eshoo on Evergreening Loophole in Biologics Bill - Dec 16, 2009 As an example, these experts describe how Amgen, the maker of Epogen® (a biologic used to treat anemia), has invoked patents to prevent competitors from ... Firedoglake (blog) Amerikanen verwachten verslechtering dialysezorg - Dec 13, 2009 ...het opnemen van Epogen (tegen bloedarmoede) in de lumpsum medicijnvergoeding om misbruik te voorkomen en het uitsluiten van de zorg door de nefroloog ... NierNieuws.nl Pfizer quer entrar no mercado de genéricos biotecnológicos - Dec 10, 2009 Segundo a Bloomberg, a empresa poderá comercializar dentro de cinco anos as primeiras cópias de fármacos injectáveis como o Epogen® (Amgen) ou o Lovenox® ... RCM Pharma Amgen und Roche beenden Patentstreit über Anämie-Mittel Mircera - Dec 23, 2009 Amgen vertreibt in den USA bereits die Anämie-Mittel "Aranesp" und "Epogen". Das Urteil beinhalte keine Zahlungen zwischen den beiden Parteien, ... manager-magazin.de Study: Some clinics profit from heavier Epogen doses. - Apr 18, 2007 Apr. 18--For-profit dialysis chains in the United States give patients larger doses of the expensive antianemia drug Epogen compared to nonprofit clinics, ... Free with registration - Boston Globe - AccessMyLibrary.com US Medicare seeks DaVita records on Epogen claims - Feb 22, 2007 CHICAGO, Feb 22 (Reuters) - DaVita Inc. (DVA.N), which runs dialysis centers, said on Thursday the US government was seeking records for claims submitted ... Reuters Study Questions Epogen Use - Nov 17, 2006 By Althea Chang 11/17/06 - 07:05 PM EST. Certain uses of anemia drugs like Amgen's(AMGN Quote) Epogen and Johnson & Johnson's(JNJ Quote) Procrit could pose ... TheStreet.com - TheStreet.com (subscription) Amgen sues Roche over alleged violation of Epogen patents - Nov 9, 2005 By Denise Lavoie. AP. BOSTON – Amgen Inc., the world's largest biotech company, sued units of the Roche Holding AG n federal court here, alleging patent ... San Diego Union - Tribune - San Diego Union Tribune Congress To Scrutinize Amgen Drug - Dec 6, 2006 The report suggests changing the way Medicare pays for Epogen, Amgen's (nasdaq: AMGN - news ... Such patients receive Epogen during dialysis treatments, ... Forbes Amgen, DaVita shares off on Epogen worries - Mar 12, 2007 CHICAGO (Reuters) - DaVita Inc. (DVA.N), the biggest provider of dialysis in the United States, saw its shares fall more than 3 percent on Monday after it ... Reuters As kidney drug doses rise, so do warnings. - Sep 14, 2006 Epogen, made by Amgen Inc., is taken by most of the 325000 Americans with ... But weekly Epogen doses for dialysis patients have increased more than 200 ... Free with registration - Boston Globe - AccessMyLibrary.com US Medicare demands proof for Amgen's Epogen bid - Sep 24, 2007 WASHINGTON, Sept 24 (Reuters) - The US Medicare agency on Monday demanded evidence that a class of anemia drugs including Amgen Inc's (AMGN.O) Epogen ... Reuters Amgen gains on osteoporosis study; quarterly results on deck - … - Jul 28, 2008 Amgen's shares have been in a slump this year due to slowed sales of Epogen and Aranesp, its flagship anti-anemia products. Sales of the medications have ... MarketWatch Amgen reports largely flat earnings - MarketWatch - Apr 24, 2008 Aranesp's forerunner, Epogen, also saw sales fall, down 11% to $554 million. ... Cowen estimated Aranesp sales of $740 million and Epogen sales of $580 ... MarketWatch Novartis' Sandoz to launch generic of Amgen's Epogen next month - Sep 11, 2007 ZURICH (Thomson Financial) - Novartis AG's Sandoz unit plans to launch its generic version of Amgen Inc's Epogen in the UK and in Germany in the coming ... Forbes Some see profiteering in clinics' use of drug. - Oct 24, 2006 The drug, Amgen Inc.'s Epogen, is a synthetic hormone that replenishes ... Medicare spends more on Epogen than on any other drug, almost $2 billion a year. ... Free with registration - Boston Globe - AccessMyLibrary.com Rivals Laying Siege to Amgen's Near Monopoly in Anemia Drugs - Dec 23, 2005 Collectively, they will spend about $7 billion this year for Epogen and Aranesp and for ... The company has sold about $22 billion worth of Epogen since its ... New York Times Anemia Warning Backs Medicare - Mar 14, 2008 Amgen manufactures all three of the anemia drugs involved _ Aranesp, Epogen and Procrit. Johnson & Johnson markets Procrit. The aggressive lobbying campaign ... FOXNews Amgen's, J&J's Anemia Drugs Get Stronger US Warning - Mar 9, 2007 Aranesp and Epogen together accounted for 47 percent of the company's revenue in 2006. Procrit, Johnson & Johnson's version of Epogen, had $3.18 billion in ... Bloomberg Biotech Behemoth - Forbes.com - Jan 10, 2005 This discovery led to Amgen's anemia drug Epogen, and trials began in 1985. ... J&J would win approval of its Epogen copy, Procrit, in 1990, ... Forbes Amgen profits surge on reduced expenses - Oct 22, 2008 The Food and Drug Administration has repeatedly updated warning labels on Aranesp and another Amgen drug, Epogen, to warn of risks of blood clots and tumor ... USA Today Doctor hits FDA on Epogen oversight. - Nov 8, 2006 Nov. 8--A Boston researcher whose clinical trial linked aggressive use of anemia drugs to an increased risk of fatal heart attacks and strokes says the ... Free with registration - Boston Globe - AccessMyLibrary.com California and the West; Amgen Posts Quadrupling of Its Profit; The... - Oct 20, 2005 Sales of Epogen, Amgen's mainstay drug, plunged 12% from the same quarter last ... Amgen said patients switching to Aranesp hurt Epogen, an anemia drug sold ... Pay-Per-View - Los Angeles Times - ProQuest Archiver Amgen to Cut Jobs, a First for the Biotech Giant - Aug 16, 2007 But recent studies have suggested that Epogen and Amgen's newer anemia drug, Aranesp, could be harmful if overused, causing blood clots and heart attacks ... New York Times Amgen Shares May Fall as US Agency Urges Epogen Cut - Dec 5, 2006 By Catherine Larkin. Dec. 5 (Bloomberg) -- Shares of Amgen Inc. may fall after the investigative arm of Congress recommended policy changes that would ... Bloomberg Amgen Beats Profit Estimates - Jan 24, 2008 Labeling and reimbursement changes and safety concerns for its erythropoiesis-stimulating agents (ESAs), such as Epogen and Aranesp, have resulted in ... TheStreet.com - TheStreet.com (subscription) George Rathmann: Amgen's Giant - Sep 19, 2005 In 1984, shortly after an Amgen scientist cloned the gene to make Epogen, Rathmann got a call ... In 1989 the US Food & Drug Administration approved Epogen. ... BusinessWeek Amgen Rejected by US Court in Epogen Patent Appeal - May 14, 2007 By Greg Stohr. May 14 (Bloomberg) -- Amgen Inc., the world's largest biotechnology company, lost a US Supreme Court bid to bolster patent protection for the ... Bloomberg Kidney Dialysis Center Deal With Amgen Blocks Roche - Oct 20, 2006 Medicare, which pays most expenses for dialysis, even for people younger than 65, is estimated to spend roughly $2 billion a year on Epogen, ... New York Times FDA adds black box to anemia drugs - Mar 7, 2008 ...based Amgen's Aranesp and Epogen, as well as Procrit, sold by New Brunswick, NJ-based Johnson & Johnson. The drugs treat the blood-disorder anemia in ... USA Today CORRECT: Amgen wins round one against Roche - MarketWatch - Aug 30, 2007 Epogen, its next-generation formulation Aranesp, and Mircera are all based on the ... 11 will be discussing the safety of Aranesp, Procrit and Epogen in the ... MarketWatch Amgen CEO Says '07 Profits Beat Forecast - Jan 8, 2008 The FDA issued a "black box" warning, its most serious, on erythropoiesis-stimulating agents, include Aranesp and Epogen, after research suggested high ... FOXNews PHARMACEUTICALS; Limits on anemia drug are advised; An FDA panel … - May 11, 2007 Epogen is prescribed to cancer patients while Aranesp and Procrit are ... Epogen is approved for such use, but doctors also have prescribed the drug for ... Pay-Per-View - Los Angeles Times - ProQuest Archiver Aranesp, Procrit, Epogen Linked to Risks of Pure Red Cell Aplasia, … - Dec 2, 2005 Dec. 2, 2005 -- The US Food and Drug Administration (FDA), Amgen Inc, and Ortho Biotech Clinical Affairs, LLC, have notified healthcare professionals via ... Medscape Amgen CEO pay drops sharply in 2007 - Apr 1, 2008 Sales of Epogen were off 1 percent. Total sales of both drugs were close to $6.2 billion in 2007, or more than 40 percent of Amgen's 2007 revenue. ... Forbes Amgen Under Fire From Congress - Mar 21, 2007 Amgen's Epogen and Aranesp combined sales were $6.6 billion in 2006, nearly half of the company's ... Medicare spends about $2 billion a year on Epogen. ... Forbes Amgen Loses Bid to Block Import of Rival Drug - Jul 8, 2006 Amgen, the world's biggest biotechnology company, is trying to stave off competition from Cera, which could rival Amgen's anemia drug Epogen. ... Pay-Per-View - Los Angeles Times - ProQuest Archiver US judge seeks expert advice on Amgen-Roche case - Mar 26, 2008 Bear Stearns analyst Mark Schoenebaum said in a conference call he expected Amgen's combined sales of Epogen and Aranesp for kidney disease to total $2.9 ... Reuters California; Amgen's Net Income Climbs 24% - Apr 22, 2005 Sales of Epogen fell 1% to $583 million, despite increased demand, ... Raymond, the Baird analyst, said investors were reacting to lower Epogen sales. ... Pay-Per-View - Los Angeles Times - ProQuest Archiver Amgen Wins Patent Battle Over Roche's Anemia Drug - Oct 24, 2007 Amgen's two anemia drugs, Epogen and Aranesp, had sales of $6.6 billion last year, ... Since then, Amgen has sold more than $25 billion of Epogen, ... New York Times Amgen 4Q Profit Climbs on Drug Sales - Jan 26, 2006 Sales of Amgen's older anemia-fighter, Epogen, fell 10 percent to $626 million ... "We expect that the cannibalization of Epogen in the hospital setting to ... San Francisco Chronicle Roche accepts court pact for US Mircera sales - Mar 18, 2008 He said Amgen's US Epogen and Aranesp sales for kidney disease represent about $1.50 per share of the $4.00 per share he expects the company to earn this ... Reuters CVS gets pickier on which drug suppliers to use - May 24, 2005 CVS unknowingly purchased and dispensed adulterated vials of anemia treatment Epogen in 2002. In its announcement Tuesday, the drugstore chain said: "CVS ... USA Today FDA warning drives doubts on Epogen drug - Mar 19, 2007 By Christopher Rowland, Globe Staff | March 19, 2007. A Food and Drug Administration warning about the use of antianemia drugs is increasing pressure on ... Boston Globe Diagnosing Amgen - Oct 25, 2006 In the US, the patents for its blockbuster anti-anemia drug, Epogen, terminate in six or seven years. “That's almost tomorrow morning for us. ... Forbes Amgen soars as new drug shows promise - Jul 29, 2008 Sales of Epogen, an older anemia drug for patients with chronic kidney ... Sales of Epogen and Aranesp, which fell 8 percent to $6.6 billion last year, ... Providence Journal Not what the doctor ordered - May 8, 2005 You'll recognize many: Lipitor, Zyprexa, Epogen, Procrit, Neupogen, and Serostim. ... To begin with, medications such as Epogen are expensive: Replacing the ... Boston Globe A Big Boost for Amgen - Sep 12, 2007 The new decision by the FDA affects the anemia drugs Epogen and Aranesp made by Amgen and Procrit made by Johnson & Johnson (JNJ) -- which are also known as ... BusinessWeek Amgen earnings beat forecast, driven by Aranesp sales - Oct. 23, 2006 - Oct 23, 2006 Sales of anemia treatment Epogen edged up 6 percent to $633 million. North American sales of Enbrel, a treatment for rheumatoid arthritis, ... CNNMoney.com FDA cites Procrit, Eprex and Eopgen study - Sep 29, 2008 In the United States, epoetin alfa is licensed by Amgen Inc. of Thousand Oaks, Calif., and is marketed as Epogen. Procrit and Eprex are marketed by Johnson ... United Press International CVS tightens up on suppliers, No.1 retail pharmacy vows not to buy... - May 26, 2005 Tim Fagan, who says he suffered severe pain while taking Epogen after a liver transplant in 2002, sued CVS after it notified him that some of the ... Pay-Per-View - Newsday - ProQuest Archiver Aranesp, Epogen, Procrit Get Another Black Box Warning - Mar 10, 2008 Aranesp, Epogen and Procrit, drugs used to treat anemia in patients undergoing chemotherapy, will soon bear new black box warnings that they may shorten ... Newsinferno.com Amgen Defends Its Turf as Competition Looms for Anemia Drug - Oct 17, 2007 Since then, Amgen has sold more than $25 billion worth of Epogen, including $2.5 billion worth last year. Most of those billions came from Medicare, ... New York Times Business | projo.com | The Providence Journal - Nov 23, 2006 Amgen sells the same drug under the brand Epogen, but under an agreement with J&J, Amgen only sells Epogen to treat anemia in kidney-dialysis patients, ... Providence Journal Amgen earnings surge 19 percent, matching forecast - Apr. 23, 2007 - Apr 23, 2007 Sales for another anemia blockbuster, Epogen, edged up 3 percent to $625 million. ... Aranesp and Epogen are often used in conjunction with chemotherapy, ... CNNMoney.com 'Tim Fagan's Law' Being Proposed To Combat Growing Problem - May 9, 2005 And eventually, according to Eban's investigation, the Epogen was sold back to one of the ... In the end, 110000 vials of Epogen and Procrit were relabeled, ... CBS News Dialysis profits may put patients at risk - Health care- msnbc.com - Apr 19, 2007 The drug is Epogen, and Medicare pays more for it than any other single drug: $2 ... Epogen is approved by the Food and Drug Administration to prevent blood ... msnbc.com Procrit, Epogen, Aranesp and other "new" ESAs. Hand me another coffi ... - Jan 3, 2008 ESA's shorten survival when the hemoglobins are elevated to "normal" levels. The entire subject will be re-reviewed by the FDA in the next few months. ... Gerson Lehrman Group Amgen's Drug Sales Surge - Jul 20, 2006 Sales of Aranesp took a bite out of revenue from Amgen's other anemia drug, Epogen, which fell 5% to $613 million in the second quarter. ... TheStreet.com - TheStreet.com (subscription) Novartis clears EU hurdle for generic biotech drug - Jun 22, 2007 Amgen , which co-developed the drug, markets it in the US under the name Epogen. Although Amgen has launched a next-generation version of Epogen called ... MarketWatch FDA Delays Approval of New Anemia Drug - May 20, 2007 If approved, Mircera would compete with Amgen's Aranesp and Epogen and Johnson and Johnson's Procrit. An FDA advisory panel last week recommended warning ... ABC News More Misery for Amgen - May 15, 2007 Policy makers are reviewing various uses for Aranesp and another Amgen anti-anemia drug, Epogen. Later this year, they could restrict uses of the drugs for ... BusinessWeek Anemia Drugs Change Black Box Warning - Nov 8, 2007 Epogen and Procrit are also approved for use in certain anemia patients who are scheduled to undergo major surgery to reduce blood transfusions during or ... WebMD Amgen's anemia woes to persist, analysts say - Jul 30, 2007 O) Aranesp and Epogen drugs face continued uncertainty ahead of key US ... "We maintain our view that Epogen is still at risk for significant market ... Reuters Hospira looking to thrive on biotech generic drugs - Jun 7, 2007 It is unclear what Hospira would sell a generic version of Epogen for because ... Hospira, though, said Epogen and similar versions amount to a $1 billion ... Pay-Per-View - Chicago Tribune - ProQuest Archiver Amgen Finds Growing Up Isn't So Easy - Aug 18, 2007 They believe that Amgen's share price does not fully take into consideration the impact of reduced sales of Aranesp and Epogen. ... New York Times FDA Issues New Warnings on Anemia Drugs - Mar 11, 2007 At issue are drugs sold under the brand names Procrit, Epogen and Aranesp. These drugs are genetically engineered versions of a natural protein, ... Washington Post US lawmakers examine Medicare anemia drug payments - Jun 26, 2007 O) Epogen, part of a class of anti-anemia drugs called ... Amgen, in written testimony submitted to lawmakers, said most Epogen use in dialysis "has been ... Reuters Amgen shares rise on optimism will win patent case - Jan 22, 2007 VX) over Amgen's anemia drug Epogen. Citing court documents filed late on Friday, analysts said it appears that a rival anemia drug made by Roche called ... Reuters Amgen Says Aranesp's Death Risk No Higher in Chemo - Apr 19, 2007 Amgen's Aranesp and an older version, Epogen, and similar anemia ... Procrit, Epogen and Aranesp are genetically engineered versions of a protein called ... Bloomberg Racing Promoters Look for Life After Armstrong - Feb 9, 2006 The California tour is almost certain to gain publicity, however, because of its title sponsor, Amgen, which makes Epogen, the genetically engineered ... New York Times Amgen cutting costs as key anemia drug sales fall - Aug 12, 2007 Amgen's Epogen and its newer and longer-lasting Aranesp were the top revenue ... "The Epogen/Aranesp franchise is under attack on several fronts," said ... Reuters RedHerring.com ~ The Business of Technology - Jan 26, 2007 And with generic versions of Epogen potentially emerging in Europe , Amgen's anemia empire could take a big hit. Some observers noted Amgen has been ... Red Herring Amgen Ekes Out Earnings Beat, Not Much More - Oct 24, 2007 Amgen's anemia drug franchise -- Aranesp and Epogen -- recorded lower ... Epogen sales were $602 million in the quarter, down 4% sequentially and 5% lower ... TheStreet.com - TheStreet.com (subscription) Affymax to start late-stage studies of anemia drug - Jul 16, 2007 O) drugs Aranesp and Epogen and sending Affymax's shares up 15 percent. ... Aranesp, Epogen, and Johnson & Johnson's (JNJ.N) rival drug Procrit are versions ... Reuters J&J, Amgen drugs again under FDA scan - Jan 4, 2008 FDA is now reviewing two latest studies which provide evidence that J&J's Procrit and Amgen's Epogen and Aranesp are more seriously related to risks for ... Money Times - The Money Times Amgen's anemia woes to persist, analysts say - Jul 27, 2007 O) Aranesp and Epogen drugs face continued uncertainty ahead of key US ... "We maintain our view that Epogen is still at risk for significant market ... Reuters CFO Resigns Amid Amgen's Struggles - Apr 10, 2007 Amgen has come under recent fire on Capitol Hill for what it charges Medicare patients for Aranesp and another popular anemia drug, Epogen. ... FOXNews Amgen stock lifts on Senate opinion on anti-anemia drugs - Sep. 5,... - Sep 5, 2007 The CMS coverage has a direct impact on Amgen's two top-selling drugs: Aranesp and Epogen, which account for about half the company's sales. ... CNNMoney.com Aranesp, Epogen and Procrit Linked to Leukemia in Some Patients - Dec 11, 2007 Aranesp, Epogen and Procrit have been linked to yet another deadly side effect. New research suggests that the anemia drugs, ... Newsinferno.com Upside seen in anemic performance: Amgen faces rivals. - Feb 28, 2007 Amgen's anemia drugs, Epogen and Aranesp, are important because they ... Amgen began selling Epogen, known clinically as epoetin alfa, or EPO, in 1989. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com US FDA staff cautious on anemia drugs' risks - May 8, 2007 More data is needed on risks with the injectable drugs -- Amgen's Aranesp and Epogen and J&J's Procrit -- the staff said. Changes to the products' labels to ... Reuters UK Some Anemia Drugs Lead to Tumor Growth, FDA Warns - Nov 9, 2007 At issue are drugs sold under the brand names Procrit, Epogen and Aranesp. They are genetically engineered versions of a natural protein that increases the ... Pay-Per-View - Washington Post - ProQuest Archiver Anemia drugs limited by CMS - Aug 3, 2007 Epogen and Aranesp and Johnson & Johnson's Procrit are used as ... For Epogen alone, annual Medicare spending for such patients from 1991 to 2004 grew from ... washingtontimes.com Fresenius Medical Care v. United States, No. 07-2299 (8th Cir. 05/16/... - May 16, 2008 The vast majority of FMC's patients receive the drug Epogen, which reduces or ... The cost of Epogen is significant. Physicians commonly prescribe it using ... $2.95 - U.S. Court of Appeals, Eighth Circuit - VersusLaw Amgen Profit Up, 2008 Outlook Steady - Jan 25, 2008 Fourth-quarter Epogen sales fell 3 percent to $638 million, and annual sales dropped 1 percent to $2.49 billion. Amgen is also facing scrutiny from New ... Sydney Morning Herald Amgen to sell $4 billion of debt in stock buyback - May 24, 2007 Aranesp and Epogen, which treat anemia in dialysis and cancer patients, accounted for 47 percent of Amgen's $14.3 billion in revenue in last year. ... Providence Journal US patent appeals court rules on Roche, Amgen fight - Mar 19, 2008 Amgen sells EPO drugs under the names Aranesp and Epogen. Sales of Aranesp alone topped $3.6 billion in 2007. Roche has US FDA approval to sell Mircera but ... Reuters Stock Market Update - Tue Apr 24 08:19:10 EDT 2007 - Apr 24, 2007 Sales of Anemia drugs Arnesp and Epogen increased 14.6% to $1.02 billion and 3% to $625 million, respectively. US Arnesp sales increased at a slower rate of ... Reuters US FDA staff to ask panel about anemia drug doses - Sep 7, 2007 The FDA staff review also said an Amgen analysis "does not support retention of several of the quality-of-life claims" on the labels of Epogen and Procrit, ... Reuters Blue Shield of Ca. curbs anti-anemia drug limits - Jul 26, 2007 The drugs at issue include Amgen's Aranesp and Epogen, and J&J's Procrit, which belong to a class ... Aranesp and Epogen, Amgen's biggest revenue drivers, ... Reuters UK US payments for anemia drugs reduced - Jul 22, 2007 Anemia drugs known as erythropoiesis-stimulating agents, or ESAs, are sold by Amgen Inc as Epogen and Aranesp and by Johnson & Johnson as Procrit. ... Sydney Morning Herald Raising the alarm on rise in fake drugs . - Apr 11, 2005 One New York man recov ering from a liver transplant discovered the Epogen he pur chased at a drugstore was a fake- containing one-twentieth of the ... Pittsburgh Post-Gazette - Google News Archive FDA stops short of approving Roche drug - May 18, 2007 ...dropped more than 15 percent in the last week due to safety concerns over treatments Aranesp and Epogen, which account for nearly half of annual sales. ... USA Today Amgen shares climb after Roche anemia appeal move - Apr 10, 2008 The older Epogen, used primarily in kidney dialysis patients, had sales of $638 million in the quarter. Credit Suisse's Aberman said investors could now ... Reuters ANALYSIS-Amgen valuation tempts, but uncertainties mount - Apr 23, 2008 The safety of anemia drugs, including Amgen's Epogen and Aranesp, has been under siege since the emergence of data more than a year ago showing that the ... Reuters UK Dialysis provider faces anemia drug pressures - Sep 17, 2007 Like its competitors, DaVita is using large volumes of the Amgen drug; however, it seems to be the most aggressive Epogen user, according to government ... FierceHealthcare US to Review Anemia Drugs for Safety - Mar 15, 2007 Use of the anemia drugs Aranesp and Epogen, made by Amgen, and Procrit, from Johnson & Johnson, ... Epogen is the single biggest drug expense for Medicare. ... New York Times Good News for Amgen | Biotech/Pharmaceuticals | Financial Articles & ... - Feb 1, 2006 Amgen sells the anemia drugs Epogen and Aranesp, which together had sales of $5.8 billion last year. Amgen is the world's biggest biotech company by market ... TheStreet.com - TheStreet.com (subscription) CORRECTED - UPDATE 1-Interim data show Aranesp no help in breast … - Nov 30, 2007 Aranesp and its predecessor Epogen were Amgen's top-selling drugs in 2006, reaping combined revenue of $6.6 billion. The entire class has been under a ... Reuters The Washington Times Health Care column - Jun 1, 2007 ...and Amgen Inc., which makes the popular Epogen, could be facing darker days as a result of their marketing practices and pricing schemes. ... Free with registration - Washington Times - AccessMyLibrary.com Profit, use of anemia drug criticized Study says private dialysis... - Apr 23, 2007 The drug is Epogen, and Medi care pays more for it than any other single drug: ... Epogen i approved by the Food and Drug Administration to prevent blood ... Milwaukee Journal Sentinel - Google News Archive Los Angeles Business Journal Online - business news and information... - Oct 25, 2007 Sales of Amgen's best-selling anemia treatments, Aranesp and Epogen, have suffered this year after studies released earlier in the year hinted that the ... Los Angeles Business Journal Business briefs -- 07/27 | Business | PE.com | Southern California... - Jul 26, 2007 Amgen shares have fallen 18 percent this year, after studies showed the company's two top-selling anemia drugs, Aranesp and Epogen, raised the risk of death ... Press-Enterprise |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |